111 related articles for article (PubMed ID: 29685206)
1. Chaos theory for clinical manifestations in multiple sclerosis.
Akaishi T; Takahashi T; Nakashima I
Med Hypotheses; 2018 Jun; 115():87-93. PubMed ID: 29685206
[TBL] [Abstract][Full Text] [Related]
2. A minimal unified model of disease trajectories captures hallmarks of multiple sclerosis.
Kannan V; Kiani NA; Piehl F; Tegner J
Math Biosci; 2017 Jul; 289():1-8. PubMed ID: 28365299
[TBL] [Abstract][Full Text] [Related]
3. Morphometric analysis of axons in the minute multiple sclerosis lesions and shadow plaques in patients with multiple sclerosis.
Nowacki P; Potemkowski A; Korwin-Piotrowska T; Nocoń D
Folia Neuropathol; 2000; 38(3):104-10. PubMed ID: 11043971
[TBL] [Abstract][Full Text] [Related]
4. [Clinical subtypes of multiple sclerosis and the immuno-pathogeneses].
Fujihara K
Nihon Rinsho; 2003 Aug; 61(8):1293-9. PubMed ID: 12962014
[TBL] [Abstract][Full Text] [Related]
5. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis.
Tauhid S; Neema M; Healy BC; Weiner HL; Bakshi R
J Neurol Sci; 2014 Nov; 346(1-2):250-4. PubMed ID: 25220114
[TBL] [Abstract][Full Text] [Related]
6. A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode.
Tutuncu M; Demirci NO; Özer F; Saip S; Kantarci OH; Siva A
Mult Scler; 2011 Oct; 17(10):1262-4. PubMed ID: 21135019
[TBL] [Abstract][Full Text] [Related]
7. Immunological differences between classical phenothypes of multiple sclerosis.
Iwanowski P; Losy J
J Neurol Sci; 2015 Feb; 349(1-2):10-4. PubMed ID: 25586536
[TBL] [Abstract][Full Text] [Related]
8. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
[TBL] [Abstract][Full Text] [Related]
9. Immunology of relapse and remission in multiple sclerosis.
Steinman L
Annu Rev Immunol; 2014; 32():257-81. PubMed ID: 24438352
[TBL] [Abstract][Full Text] [Related]
10. [Pathology and definition of multiple sclerosis].
Dutta R; Trapp BD
Rev Prat; 2006 Jun; 56(12):1293-8. PubMed ID: 16948216
[TBL] [Abstract][Full Text] [Related]
11. Gray matter atrophy in multiple sclerosis: a longitudinal study.
Fisher E; Lee JC; Nakamura K; Rudick RA
Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
[TBL] [Abstract][Full Text] [Related]
12. The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis.
Yaldizli Ö; Penner IK; Yonekawa T; Naegelin Y; Kuhle J; Pardini M; Chard DT; Stippich C; Kira JI; Bendfeldt K; Amann M; Radue EW; Kappos L; Sprenger T
Eur J Neurol; 2016 Mar; 23(3):510-9. PubMed ID: 26699999
[TBL] [Abstract][Full Text] [Related]
13. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
14. [Sex-related differences in atrophy and lesion load in multiple sclerosis patients].
Rojas JI; Patrucco L; Besada C; Funes J; Cristiano E
Neurologia; 2013 Sep; 28(7):389-93. PubMed ID: 23246218
[TBL] [Abstract][Full Text] [Related]
15. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
[TBL] [Abstract][Full Text] [Related]
16. [Dynamic paradigm in psychopathology: "chaos theory", from physics to psychiatry].
Pezard L; Nandrino JL
Encephale; 2001; 27(3):260-8. PubMed ID: 11488256
[TBL] [Abstract][Full Text] [Related]
17. Modeling the effector - regulatory T cell cross-regulation reveals the intrinsic character of relapses in Multiple Sclerosis.
Vélez de Mendizábal N; Carneiro J; Solé RV; Goñi J; Bragard J; Martinez-Forero I; Martinez-Pasamar S; Sepulcre J; Torrealdea J; Bagnato F; Garcia-Ojalvo J; Villoslada P
BMC Syst Biol; 2011 Jul; 5():114. PubMed ID: 21762505
[TBL] [Abstract][Full Text] [Related]
18. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
19. Early recognition and diagnosis of multiple sclerosis.
Waubant E
J Clin Psychiatry; 2012 Apr; 73(4):e14. PubMed ID: 22579157
[TBL] [Abstract][Full Text] [Related]
20. Influence of Peripheral inflammation on the progression of multiple sclerosis: evidence from the clinic and experimental animal models.
Murta V; Ferrari CC
Mol Cell Neurosci; 2013 Mar; 53():6-13. PubMed ID: 22771835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
